| 1 | 
                
                    TNFSF13B
                
             💬
 | [4]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network for IgA production, Rheumatoid arthritis | Belimumab 
                
                    Belimumab
                
             💬
 | 
                
                    Belimumab
                
             | [13]  11 11, 13, 43, 44, 46, 49, 51, 53, 63, 66, 222, 296, 300 💬
 | 
| 2 | 
                
                    TNFSF13B
                
             💬
 | [4]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network for IgA production, Rheumatoid arthritis | Atacicept 
                
                    Atacicept
                
             💬
 | 
                
                    Atacicept
                
             | [4]  13 13, 46, 49, 66 💬
 | 
| 3 | 
                
                    TNFSF13B
                
             💬
 | [4]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network for IgA production, Rheumatoid arthritis | Tabalumab 
                
                    Tabalumab
                
             💬
 | 
                
                    Tabalumab
                
             | [2]  46 46, 49 💬
 | 
| 4 | 
                
                    TNFSF13B
                
             💬
 | [4]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network for IgA production, Rheumatoid arthritis | Tibulizumab 
                
                    Tibulizumab
                
             💬
 | 
                
                    Tibulizumab
                
             | [1]  53 53 💬
 | 
| 5 | 
                
                    IL17F
                
             💬
 | [4]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, Inflammatory bowel disease | Bimekizumab 
                
                    Bimekizumab
                
             💬
 | 
                
                    Bimekizumab
                
             | [3]  46 46, 97, 271 💬
 | 
| 6 | 
                
                    TNFRSF13C
                
             💬
 | [5]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network for IgA production, Human T-cell leukemia virus 1 infection, Primary immunodeficiency | Ianalumab 
                
                    Ianalumab
                
             💬
 | 
                
                    Ianalumab
                
             | [7]  35 35, 46, 49, 53, 61, 63, 95 💬
 | 
| 7 | 
                
                    CCR4
                
             💬
 | [5]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Chemokine signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Viral carcinogenesis | Mogamulizumab 
                
                    Mogamulizumab
                
             💬
 | 
                
                    Mogamulizumab
                
             | [1]  26 26 💬
 | 
| 8 | 
                
                    CCR5
                
             💬
 | [11]  Viral life cycle - HIV-1 Viral life cycle - HIV-1, Virion - Human immunodeficiency virus, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Chemokine signaling pathway, Endocytosis, Toxoplasmosis, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Viral carcinogenesis | Maraviroc 
                
                    Maraviroc
                
             💬
 | 
                
                    Maraviroc
                
             | [2]  46 46, 84 💬
 | 
| 9 | 
                
                    CCR5
                
             💬
 | [11]  Viral life cycle - HIV-1 Viral life cycle - HIV-1, Virion - Human immunodeficiency virus, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Chemokine signaling pathway, Endocytosis, Toxoplasmosis, Human cytomegalovirus infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, Viral carcinogenesis | Cenicriviroc 
                
                    Cenicriviroc
                
             💬
 | 
                
                    Cenicriviroc
                
             | [1]  94 94 💬
 | 
| 10 | 
                
                    IL31RA
                
             💬
 | [2]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway | Nemolizumab 
                
                    Nemolizumab
                
             💬
 | 
                
                    Nemolizumab
                
             | [1]  51 51 💬
 | 
| 11 | 
                
                    CSF1R
                
             💬
 | [11]  MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Osteoclast differentiation, Hematopoietic cell lineage, Pathways in cancer, Transcriptional misregulation in cancer, Acute myeloid leukemia | Sunitinib 
                
                    Sunitinib
                
             💬
 | 
                
                    Sunitinib
                
             | [2]  28 28, 34 💬
 | 
| 12 | 
                
                    CSF1R
                
             💬
 | [11]  MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, PI3K-Akt signaling pathway, Osteoclast differentiation, Hematopoietic cell lineage, Pathways in cancer, Transcriptional misregulation in cancer, Acute myeloid leukemia | Pexidartinib 
                
                    Pexidartinib
                
             💬
 | 
                
                    Pexidartinib
                
             | [1]  34 34 💬
 | 
| 13 | 
                
                    CSF2
                
             💬
 | [16]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Shigellosis, Amoebiasis, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Coronavirus disease - COVID-19, Transcriptional misregulation in cancer, Acute myeloid leukemia, Rheumatoid arthritis | Otilimab 
                
                    Otilimab
                
             💬
 | 
                
                    Otilimab
                
             | [1]  46 46 💬
 | 
| 14 | 
                
                    CSF2RA
                
             💬
 | [4]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | Molgramostim 
                
                    Molgramostim
                
             💬
 | 
                
                    Molgramostim
                
             | [3]  97 97, 229, 299 💬
 | 
| 15 | 
                
                    CSF2RA
                
             💬
 | [4]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | Regramostim 
                
                    Regramostim
                
             💬
 | 
                
                    Regramostim
                
             | [1]  229 229 💬
 | 
| 16 | 
                
                    CSF2RA
                
             💬
 | [4]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | Sargramostim 
                
                    Sargramostim
                
             💬
 | 
                
                    Sargramostim
                
             | [7]  6 6, 28, 60, 62, 96, 229, 285 💬
 | 
| 17 | 
                
                    CSF2RA
                
             💬
 | [4]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | Mavrilimumab 
                
                    Mavrilimumab
                
             💬
 | 
                
                    Mavrilimumab
                
             | [2]  41 41, 46 💬
 | 
| 18 | 
                
                    CSF3R
                
             💬
 | [5]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | Filgrastim 
                
                    Filgrastim
                
             💬
 | 
                
                    Filgrastim
                
             | [35]  2 2, 6, 11, 13, 16, 22, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331 💬
 | 
| 19 | 
                
                    CSF3R
                
             💬
 | [5]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | Lenograstim 
                
                    Lenograstim
                
             💬
 | 
                
                    Lenograstim
                
             | [7]  2 2, 13, 16, 18, 19, 57, 65 💬
 | 
| 20 | 
                
                    CSF3R
                
             💬
 | [5]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | Pegfilgrastim 
                
                    Pegfilgrastim
                
             💬
 | 
                
                    Pegfilgrastim
                
             | [1]  60 60 💬
 | 
| 21 | 
                
                    EPOR
                
             💬
 | [5]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | Peginesatide 
                
                    Peginesatide
                
             💬
 | 
                
                    Peginesatide
                
             | [1]  283 283 💬
 | 
| 22 | 
                
                    IL17RA
                
             💬
 | [3]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Alcoholic liver disease | Brodalumab 
                
                    Brodalumab
                
             💬
 | 
                
                    Brodalumab
                
             | [2]  37 37, 51 💬
 | 
| 23 | 
                
                    MSTN
                
             💬
 | [1]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction | Stamulumab 
                
                    Stamulumab
                
             💬
 | 
                
                    Stamulumab
                
             | [1]  113 113 💬
 | 
| 24 | 
                
                    MSTN
                
             💬
 | [1]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction | Domagrozumab 
                
                    Domagrozumab
                
             💬
 | 
                
                    Domagrozumab
                
             | [1]  113 113 💬
 | 
| 25 | 
                
                    MSTN
                
             💬
 | [1]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction | Taldefgrobep alfa 
                
                    Taldefgrobep alfa
                
             💬
 | 
                
                    Talditercept alfa
                
             | [1]  3 3 💬
 | 
| 26 | 
                
                    MSTN
                
             💬
 | [1]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction | Apitegromab 
                
                    Apitegromab
                
             💬
 | 
                
                    Apitegromab
                
             | [1]  3 3 💬
 | 
| 27 | 
                
                    GHR
                
             💬
 | [5]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Growth hormone synthesis, secretion and action | Mecasermin 
                
                    Mecasermin
                
             💬
 | 
                
                    Mecasermin
                
             | [6]  65 65, 78, 96, 168, 265, 299 💬
 | 
| 28 | 
                
                    GHR
                
             💬
 | [5]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Growth hormone synthesis, secretion and action | Pegvisomant 
                
                    Pegvisomant
                
             💬
 | 
                
                    Pegvisomant
                
             | [2]  78 78, 265 💬
 | 
| 29 | 
                
                    GHR
                
             💬
 | [5]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Growth hormone synthesis, secretion and action | Somavaratan 
                
                    Somavaratan
                
             💬
 | 
                
                    Somavaratan
                
             | [1]  78 78 💬
 | 
| 30 | 
                
                    GHR
                
             💬
 | [5]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Growth hormone synthesis, secretion and action | Somapacitan 
                
                    Somapacitan
                
             💬
 | 
                
                    Somapacitan
                
             | [2]  78 78, 195 💬
 | 
| 31 | 
                
                    GHR
                
             💬
 | [5]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Growth hormone synthesis, secretion and action | Lonapegsomatropin 
                
                    Lonapegsomatropin
                
             💬
 | 
                
                    Lonapegsomatropin
                
             | [1]  78 78 💬
 | 
| 32 | 
                
                    IFNA1
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 33 | 
                
                    IFNA1
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 34 | 
                
                    IFNA2
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 35 | 
                
                    IFNA2
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 36 | 
                
                    IFNA4
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 37 | 
                
                    IFNA4
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 38 | 
                
                    IFNA5
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 39 | 
                
                    IFNA5
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 40 | 
                
                    IFNA6
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 41 | 
                
                    IFNA6
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 42 | 
                
                    IFNA7
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 43 | 
                
                    IFNA7
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 44 | 
                
                    IFNA8
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 45 | 
                
                    IFNA8
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 46 | 
                
                    IFNA10
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 47 | 
                
                    IFNA10
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 48 | 
                
                    IFNA13
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 49 | 
                
                    IFNA13
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 50 | 
                
                    IFNA14
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 51 | 
                
                    IFNA14
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 52 | 
                
                    IFNA16
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 53 | 
                
                    IFNA16
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 54 | 
                
                    IFNA17
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 55 | 
                
                    IFNA17
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 56 | 
                
                    IFNA21
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Rontalizumab 
                
                    Rontalizumab
                
             💬
 | 
                
                    Rontalizumab
                
             | [1]  49 49 💬
 | 
| 57 | 
                
                    IFNA21
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, Cytosolic DNA-sensing pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Alcoholic liver disease, Tuberculosis, Hepatitis C, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Autoimmune thyroid disease, Lipid and atherosclerosis | Sifalimumab 
                
                    Sifalimumab
                
             💬
 | 
                
                    Sifalimumab
                
             | [1]  49 49 💬
 | 
| 58 | 
                
                    IFNAR1
                
             💬
 | [18]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | Interferon alfa-2a 
                
                    Interferon alfa-2a
                
             💬
 | 
                
                    Interferon alfa-2a
                
             | [1]  56 56 💬
 | 
| 59 | 
                
                    IFNAR1
                
             💬
 | [18]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | Interferon beta-1b 
                
                    Interferon beta-1b
                
             💬
 | 
                
                    Interferon beta-1b
                
             | [1]  13 13 💬
 | 
| 60 | 
                
                    IFNAR1
                
             💬
 | [18]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | Interferon alfa-2b 
                
                    Interferon alfa-2b
                
             💬
 | 
                
                    Interferon alfa-2b
                
             | [2]  25 25, 34 💬
 | 
| 61 | 
                
                    IFNAR1
                
             💬
 | [18]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | Interferon alfa 
                
                    Interferon alfa
                
             💬
 | 
                
                    Interferon alfa
                
             | [6]  13 13, 25, 26, 28, 56, 96 💬
 | 
| 62 | 
                
                    IFNAR1
                
             💬
 | [18]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | Interferon beta-1a 
                
                    Interferon beta-1a
                
             💬
 | 
                
                    Interferon beta-1a
                
             | [4]  13 13, 26, 96, 97 💬
 | 
| 63 | 
                
                    IFNAR1
                
             💬
 | [18]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | Peginterferon beta-1a 
                
                    Peginterferon beta-1a
                
             💬
 | 
                
                    Peginterferon beta-1a
                
             | [1]  13 13 💬
 | 
| 64 | 
                
                    IFNAR1
                
             💬
 | [18]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | Anifrolumab 
                
                    Anifrolumab
                
             💬
 | 
                
                    Anifrolumab
                
             | [3]  46 46, 49, 53 💬
 | 
| 65 | 
                
                    IFNAR2
                
             💬
 | [17]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | Interferon alfa-2a 
                
                    Interferon alfa-2a
                
             💬
 | 
                
                    Interferon alfa-2a
                
             | [1]  56 56 💬
 | 
| 66 | 
                
                    IFNAR2
                
             💬
 | [17]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | Interferon beta-1b 
                
                    Interferon beta-1b
                
             💬
 | 
                
                    Interferon beta-1b
                
             | [1]  13 13 💬
 | 
| 67 | 
                
                    IFNAR2
                
             💬
 | [17]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | Interferon alfa-2b 
                
                    Interferon alfa-2b
                
             💬
 | 
                
                    Interferon alfa-2b
                
             | [2]  25 25, 34 💬
 | 
| 68 | 
                
                    IFNAR2
                
             💬
 | [17]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | Interferon alfa 
                
                    Interferon alfa
                
             💬
 | 
                
                    Interferon alfa
                
             | [6]  13 13, 25, 26, 28, 56, 96 💬
 | 
| 69 | 
                
                    IFNAR2
                
             💬
 | [17]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | Interferon beta-1a 
                
                    Interferon beta-1a
                
             💬
 | 
                
                    Interferon beta-1a
                
             | [4]  13 13, 26, 96, 97 💬
 | 
| 70 | 
                
                    IFNAR2
                
             💬
 | [17]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | Peginterferon beta-1a 
                
                    Peginterferon beta-1a
                
             💬
 | 
                
                    Peginterferon beta-1a
                
             | [1]  13 13 💬
 | 
| 71 | 
                
                    IFNAR2
                
             💬
 | [17]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer | Anifrolumab 
                
                    Anifrolumab
                
             💬
 | 
                
                    Anifrolumab
                
             | [3]  46 46, 49, 53 💬
 | 
| 72 | 
                
                    IFNG
                
             💬
 | [32]  Proteasome Proteasome, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Type I diabetes mellitus, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Influenza A, Herpes simplex virus 1 infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Fluid shear stress and atherosclerosis | Fontolizumab 
                
                    Fontolizumab
                
             💬
 | 
                
                    Fontolizumab
                
             | [1]  46 46 💬
 | 
| 73 | 
                
                    IFNG
                
             💬
 | [32]  Proteasome Proteasome, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Type I diabetes mellitus, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Influenza A, Herpes simplex virus 1 infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Fluid shear stress and atherosclerosis | Emapalumab 
                
                    Emapalumab
                
             💬
 | 
                
                    Emapalumab
                
             | [3]  49 49, 65, 107 💬
 | 
| 74 | 
                
                    IFNGR1
                
             💬
 | [18]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Necroptosis, Osteoclast differentiation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Chagas disease, Toxoplasmosis, Tuberculosis, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease | Interferon gamma-1b 
                
                    Interferon gamma-1b
                
             💬
 | 
                
                    Interferon gamma-1b
                
             | [7]  18 18, 65, 85, 228, 299, 301, 326 💬
 | 
| 75 | 
                
                    IFNGR2
                
             💬
 | [17]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Necroptosis, Osteoclast differentiation, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, Leishmaniasis, Chagas disease, Toxoplasmosis, Tuberculosis, Influenza A, Herpes simplex virus 1 infection, Pathways in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Inflammatory bowel disease | Interferon gamma-1b 
                
                    Interferon gamma-1b
                
             💬
 | 
                
                    Interferon gamma-1b
                
             | [7]  18 18, 65, 85, 228, 299, 301, 326 💬
 | 
| 76 | 
                
                    IL1A
                
             💬
 | [21]  MAPK signaling pathway MAPK signaling pathway, Cytokine-cytokine receptor interaction, Necroptosis, Cellular senescence, Osteoclast differentiation, Hematopoietic cell lineage, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Leishmaniasis, Tuberculosis, Measles, Influenza A, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Fluid shear stress and atherosclerosis | Pirfenidone 
                
                    Pirfenidone
                
             💬
 | 
                
                    Pirfenidone
                
             | [11]  13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
 | 
| 77 | 
                
                    IL1A
                
             💬
 | [21]  MAPK signaling pathway MAPK signaling pathway, Cytokine-cytokine receptor interaction, Necroptosis, Cellular senescence, Osteoclast differentiation, Hematopoietic cell lineage, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Leishmaniasis, Tuberculosis, Measles, Influenza A, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Fluid shear stress and atherosclerosis | Rilonacept 
                
                    Rilonacept
                
             💬
 | 
                
                    Rilonacept
                
             | [4]  51 51, 106, 107, 266 💬
 | 
| 78 | 
                
                    IL1A
                
             💬
 | [21]  MAPK signaling pathway MAPK signaling pathway, Cytokine-cytokine receptor interaction, Necroptosis, Cellular senescence, Osteoclast differentiation, Hematopoietic cell lineage, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Leishmaniasis, Tuberculosis, Measles, Influenza A, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Fluid shear stress and atherosclerosis | Bermekimab 
                
                    Bermekimab
                
             💬
 | 
                
                    Bermekimab
                
             | [1]  51 51 💬
 | 
| 79 | 
                
                    IL1B
                
             💬
 | [44]  Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Measles, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | Pirfenidone 
                
                    Pirfenidone
                
             💬
 | 
                
                    Pirfenidone
                
             | [11]  13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
 | 
| 80 | 
                
                    IL1B
                
             💬
 | [44]  Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Measles, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | Rilonacept 
                
                    Rilonacept
                
             💬
 | 
                
                    Rilonacept
                
             | [4]  51 51, 106, 107, 266 💬
 | 
| 81 | 
                
                    IL1B
                
             💬
 | [44]  Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Measles, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | Canakinumab 
                
                    Canakinumab
                
             💬
 | 
                
                    Canakinumab
                
             | [10]  46 46, 56, 84, 106, 107, 108, 113, 266, 267, 269 💬
 | 
| 82 | 
                
                    IL1B
                
             💬
 | [44]  Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Measles, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | Gevokizumab 
                
                    Gevokizumab
                
             💬
 | 
                
                    Gevokizumab
                
             | [4]  41 41, 50, 56, 269 💬
 | 
| 83 | 
                
                    IL1R1
                
             💬
 | [13]  MAPK signaling pathway MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Hematopoietic cell lineage, Th17 cell differentiation, Inflammatory mediator regulation of TRP channels, Pathogenic Escherichia coli infection, Shigellosis, Amoebiasis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Fluid shear stress and atherosclerosis | Anakinra 
                
                    Anakinra
                
             💬
 | 
                
                    Anakinra
                
             | [18]  2 2, 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
 | 
| 84 | 
                
                    IL2RA
                
             💬
 | [11]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer | Aldesleukin 
                
                    Aldesleukin
                
             💬
 | 
                
                    Aldesleukin
                
             | [6]  2 2, 35, 49, 65, 96, 97 💬
 | 
| 85 | 
                
                    IL2RA
                
             💬
 | [11]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer | Basiliximab 
                
                    Basiliximab
                
             💬
 | 
                
                    Basiliximab
                
             | [6]  2 2, 50, 66, 97, 222, 228 💬
 | 
| 86 | 
                
                    IL2RA
                
             💬
 | [11]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer | Daclizumab 
                
                    Daclizumab
                
             💬
 | 
                
                    Daclizumab
                
             | [8]  13 13, 56, 60, 65, 97, 107, 283, 284 💬
 | 
| 87 | 
                
                    IL2RB
                
             💬
 | [11]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer, Transcriptional misregulation in cancer | Aldesleukin 
                
                    Aldesleukin
                
             💬
 | 
                
                    Aldesleukin
                
             | [6]  2 2, 35, 49, 65, 96, 97 💬
 | 
| 88 | 
                
                    IL2RG
                
             💬
 | [12]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer, Inflammatory bowel disease, Primary immunodeficiency | Aldesleukin 
                
                    Aldesleukin
                
             💬
 | 
                
                    Aldesleukin
                
             | [6]  2 2, 35, 49, 65, 96, 97 💬
 | 
| 89 | 
                
                    IL4
                
             💬
 | [16]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Intestinal immune network for IgA production, Leishmaniasis, Pathways in cancer, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Allograft rejection | Binetrakin 
                
                    Binetrakin
                
             💬
 | 
                
                    Binetrakin
                
             | [1]  46 46 💬
 | 
| 90 | 
                
                    IL4R
                
             💬
 | [8]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Pathways in cancer, Inflammatory bowel disease | Dupilumab 
                
                    Dupilumab
                
             💬
 | 
                
                    Dupilumab
                
             | [5]  51 51, 97, 98, 160, 162 💬
 | 
| 91 | 
                
                    IL5
                
             💬
 | [13]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th1 and Th2 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Intestinal immune network for IgA production, Pathways in cancer, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Allograft rejection | Mepolizumab 
                
                    Mepolizumab
                
             💬
 | 
                
                    Mepolizumab
                
             | [4]  44 44, 45, 98, 162 💬
 | 
| 92 | 
                
                    IL5
                
             💬
 | [13]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th1 and Th2 cell differentiation, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, Intestinal immune network for IgA production, Pathways in cancer, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Allograft rejection | Reslizumab 
                
                    Reslizumab
                
             💬
 | 
                
                    Reslizumab
                
             | [2]  44 44, 98 💬
 | 
| 93 | 
                
                    IL5RA
                
             💬
 | [4]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer | Benralizumab 
                
                    Benralizumab
                
             💬
 | 
                
                    Benralizumab
                
             | [5]  44 44, 45, 98, 162, 299 💬
 | 
| 94 | 
                
                    IL6
                
             💬
 | [51]  EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Antifolate resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, Cellular senescence, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | Pirfenidone 
                
                    Pirfenidone
                
             💬
 | 
                
                    Pirfenidone
                
             | [11]  13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
 | 
| 95 | 
                
                    IL6
                
             💬
 | [51]  EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Antifolate resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, Cellular senescence, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | Pomalidomide 
                
                    Pomalidomide
                
             💬
 | 
                
                    Pomalidomide
                
             | [5]  28 28, 51, 85, 227, 331 💬
 | 
| 96 | 
                
                    IL6
                
             💬
 | [51]  EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Antifolate resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, Cellular senescence, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | Siltuximab 
                
                    Siltuximab
                
             💬
 | 
                
                    Siltuximab
                
             | [2]  28 28, 331 💬
 | 
| 97 | 
                
                    IL6
                
             💬
 | [51]  EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Antifolate resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, Cellular senescence, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | Sirukumab 
                
                    Sirukumab
                
             💬
 | 
                
                    Sirukumab
                
             | [2]  41 41, 46 💬
 | 
| 98 | 
                
                    IL6
                
             💬
 | [51]  EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Antifolate resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, Cellular senescence, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Lipid and atherosclerosis | Olokizumab 
                
                    Olokizumab
                
             💬
 | 
                
                    Olokizumab
                
             | [2]  46 46, 96 💬
 | 
| 99 | 
                
                    IL6R
                
             💬
 | [12]  EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th17 cell differentiation, Non-alcoholic fatty liver disease, Human cytomegalovirus infection, Coronavirus disease - COVID-19, Pathways in cancer | Tocilizumab 
                
                    Tocilizumab
                
             💬
 | 
                
                    Tocilizumab
                
             | [21]  2 2, 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
 | 
| 100 | 
                
                    IL6R
                
             💬
 | [12]  EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th17 cell differentiation, Non-alcoholic fatty liver disease, Human cytomegalovirus infection, Coronavirus disease - COVID-19, Pathways in cancer | Sarilumab 
                
                    Sarilumab
                
             💬
 | 
                
                    Sarilumab
                
             | [5]  41 41, 46, 84, 107, 271 💬
 | 
| 101 | 
                
                    IL6R
                
             💬
 | [12]  EGFR tyrosine kinase inhibitor resistance EGFR tyrosine kinase inhibitor resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th17 cell differentiation, Non-alcoholic fatty liver disease, Human cytomegalovirus infection, Coronavirus disease - COVID-19, Pathways in cancer | Satralizumab 
                
                    Satralizumab
                
             💬
 | 
                
                    Satralizumab
                
             | [3]  11 11, 13, 86 💬
 | 
| 102 | 
                
                    CXCR1
                
             💬
 | [6]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Chemokine signaling pathway, Phospholipase D signaling pathway, Endocytosis, Epithelial cell signaling in Helicobacter pylori infection | Reparixin 
                
                    Reparixin
                
             💬
 | 
                
                    Reparixin
                
             | [2]  298 298, 299 💬
 | 
| 103 | 
                
                    CXCR2
                
             💬
 | [7]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Chemokine signaling pathway, Phospholipase D signaling pathway, Endocytosis, Epithelial cell signaling in Helicobacter pylori infection, Human cytomegalovirus infection | Reparixin 
                
                    Reparixin
                
             💬
 | 
                
                    Reparixin
                
             | [2]  298 298, 299 💬
 | 
| 104 | 
                
                    IL10
                
             💬
 | [22]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, FoxO signaling pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, T cell receptor signaling pathway, Intestinal immune network for IgA production, Pertussis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Staphylococcus aureus infection, Tuberculosis, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Allograft rejection | Pirfenidone 
                
                    Pirfenidone
                
             💬
 | 
                
                    Pirfenidone
                
             | [11]  13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
 | 
| 105 | 
                
                    IL11RA
                
             💬
 | [3]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Hematopoietic cell lineage | Oprelvekin 
                
                    Oprelvekin
                
             💬
 | 
                
                    Oprelvekin
                
             | [2]  96 96, 288 💬
 | 
| 106 | 
                
                    IL12A
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Alcoholic liver disease, Type I diabetes mellitus, Pertussis, Legionellosis, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Measles, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Inflammatory bowel disease, Allograft rejection, Lipid and atherosclerosis | Ustekinumab 
                
                    Ustekinumab
                
             💬
 | 
                
                    Ustekinumab
                
             | [16]  37 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
 | 
| 107 | 
                
                    IL12B
                
             💬
 | [25]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Toll-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th1 and Th2 cell differentiation, Alcoholic liver disease, Type I diabetes mellitus, Pertussis, Legionellosis, Leishmaniasis, Chagas disease, African trypanosomiasis, Toxoplasmosis, Amoebiasis, Tuberculosis, Measles, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Pathways in cancer, Proteoglycans in cancer, Inflammatory bowel disease, Allograft rejection, Lipid and atherosclerosis | Ustekinumab 
                
                    Ustekinumab
                
             💬
 | 
                
                    Ustekinumab
                
             | [16]  37 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
 | 
| 108 | 
                
                    IL13
                
             💬
 | [8]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Fc epsilon RI signaling pathway, Pathways in cancer, Asthma, Inflammatory bowel disease | Anrukinzumab 
                
                    Anrukinzumab
                
             💬
 | 
                
                    Anrukinzumab
                
             | [1]  97 97 💬
 | 
| 109 | 
                
                    IL13
                
             💬
 | [8]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Fc epsilon RI signaling pathway, Pathways in cancer, Asthma, Inflammatory bowel disease | Lebrikizumab 
                
                    Lebrikizumab
                
             💬
 | 
                
                    Lebrikizumab
                
             | [1]  85 85 💬
 | 
| 110 | 
                
                    IL13
                
             💬
 | [8]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, IL-17 signaling pathway, Th1 and Th2 cell differentiation, Fc epsilon RI signaling pathway, Pathways in cancer, Asthma, Inflammatory bowel disease | Tralokinumab 
                
                    Tralokinumab
                
             💬
 | 
                
                    Tralokinumab
                
             | [2]  85 85, 97 💬
 | 
| 111 | 
                
                    IL17A
                
             💬
 | [6]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, Alcoholic liver disease, Inflammatory bowel disease, Rheumatoid arthritis | Secukinumab 
                
                    Secukinumab
                
             💬
 | 
                
                    Secukinumab
                
             | [8]  13 13, 37, 41, 46, 107, 160, 269, 271 💬
 | 
| 112 | 
                
                    IL17A
                
             💬
 | [6]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, Alcoholic liver disease, Inflammatory bowel disease, Rheumatoid arthritis | Ixekizumab 
                
                    Ixekizumab
                
             💬
 | 
                
                    Ixekizumab
                
             | [8]  36 36, 37, 46, 107, 160, 162, 269, 271 💬
 | 
| 113 | 
                
                    IL17A
                
             💬
 | [6]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, Alcoholic liver disease, Inflammatory bowel disease, Rheumatoid arthritis | Tibulizumab 
                
                    Tibulizumab
                
             💬
 | 
                
                    Tibulizumab
                
             | [1]  53 53 💬
 | 
| 114 | 
                
                    IL17A
                
             💬
 | [6]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, Alcoholic liver disease, Inflammatory bowel disease, Rheumatoid arthritis | Bimekizumab 
                
                    Bimekizumab
                
             💬
 | 
                
                    Bimekizumab
                
             | [3]  46 46, 97, 271 💬
 | 
| 115 | 
                
                    LEPR
                
             💬
 | [6]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, AMPK signaling pathway, JAK-STAT signaling pathway, Adipocytokine signaling pathway, Non-alcoholic fatty liver disease | Metreleptin 
                
                    Metreleptin
                
             💬
 | 
                
                    Metreleptin
                
             | [1]  265 265 💬
 | 
| 116 | 
                
                    LTA
                
             💬
 | [7]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, TNF signaling pathway, Type I diabetes mellitus, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection | Etanercept 
                
                    Etanercept
                
             💬
 | 
                
                    Etanercept
                
             | [16]  15 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 107, 228, 270, 271, 285 💬
 | 
| 117 | 
                
                    LTA
                
             💬
 | [7]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, TNF signaling pathway, Type I diabetes mellitus, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection | Pateclizumab 
                
                    Pateclizumab
                
             💬
 | 
                
                    Pateclizumab
                
             | [1]  46 46 💬
 | 
| 118 | 
                
                    LTB
                
             💬
 | [3]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Rheumatoid arthritis | Baminercept 
                
                    Baminercept
                
             💬
 | 
                
                    Baminercept
                
             | [4]  13 13, 46, 53, 97 💬
 | 
| 119 | 
                
                    MPL
                
             💬
 | [2]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway | Romiplostim 
                
                    Romiplostim
                
             💬
 | 
                
                    Romiplostim
                
             | [4]  60 60, 63, 64, 65 💬
 | 
| 120 | 
                
                    MPL
                
             💬
 | [2]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway | Avatrombopag 
                
                    Avatrombopag
                
             💬
 | 
                
                    Avatrombopag
                
             | [2]  60 60, 63 💬
 | 
| 121 | 
                
                    NGF
                
             💬
 | [9]  MAPK signaling pathway MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Apoptosis, Neurotrophin signaling pathway, Inflammatory mediator regulation of TRP channels | Tanezumab 
                
                    Tanezumab
                
             💬
 | 
                
                    Tanezumab
                
             | [2]  226 226, 298 💬
 | 
| 122 | 
                
                    NGFR
                
             💬
 | [9]  Virion - Lyssavirus Virion - Lyssavirus, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Apoptosis - multiple species, Neurotrophin signaling pathway, Transcriptional misregulation in cancer | Cenegermin 
                
                    Cenegermin
                
             💬
 | 
                
                    Cenegermin
                
             | [2]  53 53, 90 💬
 | 
| 123 | 
                
                    IL20
                
             💬
 | [3]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, JAK-STAT signaling pathway | Fletikumab 
                
                    Fletikumab
                
             💬
 | 
                
                    Fletikumab
                
             | [1]  46 46 💬
 | 
| 124 | 
                
                    IL22
                
             💬
 | [4]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway, Th17 cell differentiation, Inflammatory bowel disease | Efmarodocokin alfa 
                
                    Efmarodocokin alfa
                
             💬
 | 
                
                    Efmarodocokin alfa
                
             | [2]  96 96, 97 💬
 | 
| 125 | 
                
                    IL23A
                
             💬
 | [9]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis | Ustekinumab 
                
                    Ustekinumab
                
             💬
 | 
                
                    Ustekinumab
                
             | [16]  37 37, 40, 41, 46, 49, 50, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
 | 
| 126 | 
                
                    IL23A
                
             💬
 | [9]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis | Tildrakizumab 
                
                    Tildrakizumab
                
             💬
 | 
                
                    Tildrakizumab
                
             | [2]  162 162, 271 💬
 | 
| 127 | 
                
                    IL23A
                
             💬
 | [9]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis | Guselkumab 
                
                    Guselkumab
                
             💬
 | 
                
                    Guselkumab
                
             | [5]  37 37, 41, 51, 96, 97 💬
 | 
| 128 | 
                
                    IL23A
                
             💬
 | [9]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis | Brazikumab 
                
                    Brazikumab
                
             💬
 | 
                
                    Brazikumab
                
             | [2]  96 96, 97 💬
 | 
| 129 | 
                
                    IL23A
                
             💬
 | [9]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis | Risankizumab 
                
                    Risankizumab
                
             💬
 | 
                
                    Risankizumab
                
             | [4]  37 37, 96, 97, 271 💬
 | 
| 130 | 
                
                    IL23A
                
             💬
 | [9]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Th17 cell differentiation, Pertussis, Tuberculosis, Pathways in cancer, Inflammatory bowel disease, Rheumatoid arthritis | Mirikizumab 
                
                    Mirikizumab
                
             💬
 | 
                
                    Mirikizumab
                
             | [3]  37 37, 96, 97 💬
 | 
| 131 | 
                
                    PRL
                
             💬
 | [5]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Prolactin signaling pathway | Cabergoline 
                
                    Cabergoline
                
             💬
 | 
                
                    Cabergoline
                
             | [3]  6 6, 74, 75 💬
 | 
| 132 | 
                
                    PRL
                
             💬
 | [5]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Prolactin signaling pathway | Terguride 
                
                    Terguride
                
             💬
 | 
                
                    Terguride
                
             | [2]  51 51, 86 💬
 | 
| 133 | 
                
                    PRL
                
             💬
 | [5]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Prolactin signaling pathway | Bromocriptine 
                
                    Bromocriptine
                
             💬
 | 
                
                    Bromocriptine
                
             | [2]  6 6, 74 💬
 | 
| 134 | 
                
                    TNFRSF17
                
             💬
 | [2]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production | Belantamab mafodotin 
                
                    Belantamab mafodotin
                
             💬
 | 
                
                    Belantamab mafodotin
                
             | [1]  28 28 💬
 | 
| 135 | 
                
                    CCL2
                
             💬
 | [17]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Chemokine signaling pathway, NOD-like receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, AGE-RAGE signaling pathway in diabetic complications, Yersinia infection, Chagas disease, Malaria, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Rheumatoid arthritis, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | Pirfenidone 
                
                    Pirfenidone
                
             💬
 | 
                
                    Pirfenidone
                
             | [11]  13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
 | 
| 136 | 
                
                    TGFB1
                
             💬
 | [34]  MAPK signaling pathway MAPK signaling pathway, Cytokine-cytokine receptor interaction, FoxO signaling pathway, Cell cycle, Cellular senescence, TGF-beta signaling pathway, Osteoclast differentiation, Hippo signaling pathway, Th17 cell differentiation, Intestinal immune network for IgA production, Relaxin signaling pathway, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Leishmaniasis, Chagas disease, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis B, Human T-cell leukemia virus 1 infection, Pathways in cancer, Proteoglycans in cancer, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Chronic myeloid leukemia, Hepatocellular carcinoma, Gastric cancer, Inflammatory bowel disease, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Diabetic cardiomyopathy | Fresolimumab 
                
                    Fresolimumab
                
             💬
 | 
                
                    Fresolimumab
                
             | [3]  51 51, 85, 222 💬
 | 
| 137 | 
                
                    TGFB2
                
             💬
 | [31]  MAPK signaling pathway MAPK signaling pathway, Cytokine-cytokine receptor interaction, FoxO signaling pathway, Cell cycle, Cellular senescence, TGF-beta signaling pathway, Osteoclast differentiation, Hippo signaling pathway, AGE-RAGE signaling pathway in diabetic complications, Leishmaniasis, Chagas disease, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis B, Human T-cell leukemia virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Chronic myeloid leukemia, Hepatocellular carcinoma, Gastric cancer, Inflammatory bowel disease, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Diabetic cardiomyopathy | Fresolimumab 
                
                    Fresolimumab
                
             💬
 | 
                
                    Fresolimumab
                
             | [3]  51 51, 85, 222 💬
 | 
| 138 | 
                
                    TGFB3
                
             💬
 | [28]  MAPK signaling pathway MAPK signaling pathway, Cytokine-cytokine receptor interaction, FoxO signaling pathway, Cell cycle, Cellular senescence, TGF-beta signaling pathway, Hippo signaling pathway, AGE-RAGE signaling pathway in diabetic complications, Leishmaniasis, Chagas disease, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis B, Human T-cell leukemia virus 1 infection, Pathways in cancer, Colorectal cancer, Renal cell carcinoma, Pancreatic cancer, Chronic myeloid leukemia, Hepatocellular carcinoma, Gastric cancer, Inflammatory bowel disease, Rheumatoid arthritis, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Diabetic cardiomyopathy | Fresolimumab 
                
                    Fresolimumab
                
             💬
 | 
                
                    Fresolimumab
                
             | [3]  51 51, 85, 222 💬
 | 
| 139 | 
                
                    TNF
                
             💬
 | [67]  Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | Etanercept 
                
                    Etanercept
                
             💬
 | 
                
                    Etanercept
                
             | [16]  15 15, 28, 35, 38, 39, 46, 50, 53, 56, 60, 85, 107, 228, 270, 271, 285 💬
 | 
| 140 | 
                
                    TNF
                
             💬
 | [67]  Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | Thalidomide 
                
                    Thalidomide
                
             💬
 | 
                
                    Thalidomide
                
             | [20]  2 2, 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 💬
 | 
| 141 | 
                
                    TNF
                
             💬
 | [67]  Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | Pirfenidone 
                
                    Pirfenidone
                
             💬
 | 
                
                    Pirfenidone
                
             | [11]  13 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228 💬
 | 
| 142 | 
                
                    TNF
                
             💬
 | [67]  Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | Adalimumab 
                
                    Adalimumab
                
             💬
 | 
                
                    Adalimumab
                
             | [17]  19 19, 37, 40, 41, 46, 56, 84, 96, 97, 107, 160, 164, 222, 226, 269, 270, 271 💬
 | 
| 143 | 
                
                    TNF
                
             💬
 | [67]  Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | Infliximab 
                
                    Infliximab
                
             💬
 | 
                
                    Infliximab
                
             | [27]  35 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 85, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 💬
 | 
| 144 | 
                
                    TNF
                
             💬
 | [67]  Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | Certolizumab pegol 
                
                    Certolizumab pegol
                
             💬
 | 
                
                    Certolizumab pegol
                
             | [8]  37 37, 46, 49, 96, 97, 107, 226, 271 💬
 | 
| 145 | 
                
                    TNF
                
             💬
 | [67]  Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | Golimumab 
                
                    Golimumab
                
             💬
 | 
                
                    Golimumab
                
             | [8]  46 46, 56, 84, 96, 97, 107, 270, 271 💬
 | 
| 146 | 
                
                    TNF
                
             💬
 | [67]  Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | Lenalidomide 
                
                    Lenalidomide
                
             💬
 | 
                
                    Lenalidomide
                
             | [8]  16 16, 26, 28, 34, 49, 284, 300, 331 💬
 | 
| 147 | 
                
                    TNF
                
             💬
 | [67]  Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | Pegsunercept 
                
                    Pegsunercept
                
             💬
 | 
                
                    Pegsunercept
                
             | [1]  46 46 💬
 | 
| 148 | 
                
                    TNF
                
             💬
 | [67]  Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | Pomalidomide 
                
                    Pomalidomide
                
             💬
 | 
                
                    Pomalidomide
                
             | [5]  28 28, 51, 85, 227, 331 💬
 | 
| 149 | 
                
                    TNF
                
             💬
 | [67]  Antifolate resistance Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis | Ozoralizumab 
                
                    Ozoralizumab
                
             💬
 | 
                
                    Ozoralizumab
                
             | [1]  46 46 💬
 | 
| 150 | 
                
                    CCR2
                
             💬
 | [3]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Chemokine signaling pathway | Cenicriviroc 
                
                    Cenicriviroc
                
             💬
 | 
                
                    Cenicriviroc
                
             | [1]  94 94 💬
 | 
| 151 | 
                
                    IL1R2
                
             💬
 | [7]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Amoebiasis, Human T-cell leukemia virus 1 infection, Transcriptional misregulation in cancer, Prostate cancer, Fluid shear stress and atherosclerosis | Anakinra 
                
                    Anakinra
                
             💬
 | 
                
                    Anakinra
                
             | [18]  2 2, 13, 15, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299 💬
 | 
| 152 | 
                
                    CXCR4
                
             💬
 | [14]  Viral life cycle - HIV-1 Viral life cycle - HIV-1, Virion - Human immunodeficiency virus, Calcium signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Chemokine signaling pathway, Endocytosis, Axon guidance, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Pathways in cancer | Plerixafor 
                
                    Plerixafor
                
             💬
 | 
                
                    Plerixafor
                
             | [5]  19 19, 20, 65, 285, 299 💬
 | 
| 153 | 
                
                    TSLP
                
             💬
 | [2]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway | Tezepelumab 
                
                    Tezepelumab
                
             💬
 | 
                
                    Tezepelumab
                
             | [1]  98 98 💬
 | 
| 154 | 
                
                    TNFSF11
                
             💬
 | [8]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Prolactin signaling pathway, Parathyroid hormone synthesis, secretion and action, Chemical carcinogenesis - receptor activation, Breast cancer, Rheumatoid arthritis | Denosumab 
                
                    Denosumab
                
             💬
 | 
                
                    Denosumab
                
             | [8]  46 46, 50, 70, 93, 95, 96, 274, 299 💬
 | 
| 155 | 
                
                    TNFSF13
                
             💬
 | [3]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, Rheumatoid arthritis | Atacicept 
                
                    Atacicept
                
             💬
 | 
                
                    Atacicept
                
             | [4]  13 13, 46, 49, 66 💬
 | 
| 156 | 
                
                    IL1RL2
                
             💬
 | [1]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction | Imsidolimab 
                
                    Imsidolimab
                
             💬
 | 
                
                    Imsidolimab
                
             | [1]  37 37 💬
 | 
| 157 | 
                
                    IL1RL2
                
             💬
 | [1]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction | Spesolimab 
                
                    Spesolimab
                
             💬
 | 
                
                    Spesolimab
                
             | [3]  37 37, 96, 97 💬
 | 
| 158 | 
                
                    CD4
                
             💬
 | [14]  Viral life cycle - HIV-1 Viral life cycle - HIV-1, Virion - Human immunodeficiency virus, Cytokine-cytokine receptor interaction, Cell adhesion molecules, Antigen processing and presentation, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, Yersinia infection, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency | Zanolimumab 
                
                    Zanolimumab
                
             💬
 | 
                
                    Zanolimumab
                
             | [1]  46 46 💬
 | 
| 159 | 
                
                    ACVR2A
                
             💬
 | [4]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, TGF-beta signaling pathway, Signaling pathways regulating pluripotency of stem cells, Fluid shear stress and atherosclerosis | Sotatercept 
                
                    Sotatercept
                
             💬
 | 
                
                    Sotatercept
                
             | [2]  86 86, 284 💬
 | 
| 160 | 
                
                    ACVR2A
                
             💬
 | [4]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, TGF-beta signaling pathway, Signaling pathways regulating pluripotency of stem cells, Fluid shear stress and atherosclerosis | Bimagrumab 
                
                    Bimagrumab
                
             💬
 | 
                
                    Bimagrumab
                
             | [1]  15 15 💬
 | 
| 161 | 
                
                    ACVR2B
                
             💬
 | [4]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, TGF-beta signaling pathway, Signaling pathways regulating pluripotency of stem cells, Fluid shear stress and atherosclerosis | Bimagrumab 
                
                    Bimagrumab
                
             💬
 | 
                
                    Bimagrumab
                
             | [1]  15 15 💬
 | 
| 162 | 
                
                    ACVR2B
                
             💬
 | [4]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, TGF-beta signaling pathway, Signaling pathways regulating pluripotency of stem cells, Fluid shear stress and atherosclerosis | Luspatercept 
                
                    Luspatercept
                
             💬
 | 
                
                    Luspatercept
                
             | [1]  60 60 💬
 | 
| 163 | 
                
                    TNFRSF8
                
             💬
 | [1]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction | Brentuximab vedotin 
                
                    Brentuximab vedotin
                
             💬
 | 
                
                    Brentuximab vedotin
                
             | [2]  49 49, 51 💬
 | 
| 164 | 
                
                    CD40
                
             💬
 | [17]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Malaria, Toxoplasmosis, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Transcriptional misregulation in cancer, Asthma, Autoimmune thyroid disease, Systemic lupus erythematosus, Allograft rejection, Primary immunodeficiency, Viral myocarditis, Lipid and atherosclerosis | Bleselumab 
                
                    Bleselumab
                
             💬
 | 
                
                    Bleselumab
                
             | [1]  222 222 💬
 | 
| 165 | 
                
                    CD40
                
             💬
 | [17]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Malaria, Toxoplasmosis, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Transcriptional misregulation in cancer, Asthma, Autoimmune thyroid disease, Systemic lupus erythematosus, Allograft rejection, Primary immunodeficiency, Viral myocarditis, Lipid and atherosclerosis | Ravagalimab 
                
                    Ravagalimab
                
             💬
 | 
                
                    Ravagalimab
                
             | [2]  53 53, 97 💬
 | 
| 166 | 
                
                    CD40
                
             💬
 | [17]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Malaria, Toxoplasmosis, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Transcriptional misregulation in cancer, Asthma, Autoimmune thyroid disease, Systemic lupus erythematosus, Allograft rejection, Primary immunodeficiency, Viral myocarditis, Lipid and atherosclerosis | Iscalimab 
                
                    Iscalimab
                
             💬
 | 
                
                    Iscalimab
                
             | [2]  49 49, 53 💬
 | 
| 167 | 
                
                    CD40LG
                
             💬
 | [14]  Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Cell adhesion molecules, T cell receptor signaling pathway, Intestinal immune network for IgA production, Malaria, Toxoplasmosis, Asthma, Autoimmune thyroid disease, Systemic lupus erythematosus, Allograft rejection, Primary immunodeficiency, Viral myocarditis, Lipid and atherosclerosis | Toralizumab 
                
                    Toralizumab
                
             💬
 | 
                
                    Toralizumab
                
             | [1]  63 63 💬
 |